Intravenous ancrod for treatment of acute ischemic stroke. The STAT study: A randomized controlled trial

JAMA

Volumn 283, Issue 18, 2000, Pages 2395-2403

  Sherman, David G ^a   Atkinson, Richard P ^b   Chippendale, Thomas ^b   Levin, Kenneth A ^b   Ng, Ken ^b   Futrell, Nancy ^b   Hsu, Chung Y ^b   Levy, David E ^b  

^a Mays Cancer Center at UT Health San Antonio   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANCROD; ANTIFIBRINOLYTIC AGENT; FIBRINOGEN; PLACEBO; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FIBRINOGEN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0034630876     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.283.18.2395     Document Type: Article

References (37)

1. Bell W, Pitney W, Oakley L, Goodwin JF. Therapeutic defibrination in the treatment of thrombotic disease. Lancet. 1968;1:490-493.
2. Reid H, Chan K, Thean P. Prolonged coagulation defect (defibrination syndrome) in Malayan viper bite. Lancet. 1963;1:621-626.
3. Chan KE, Rizza CR, Henderson MP. A study of the coagulant properties of Malayan pit-viper venom. Br J Haematol. 1965;11:646-653.
4. Ehrly AM. Influence of arwin on the flow properties of blood. Biorheology. 1973;10:453-456.
5. Pollack VE, Glas-Greenwalt P, Olinger CP, Wadhwa NK, Myre SA. Ancrod causes rapid thrombolysis in patients with acute stroke. Am J Med Sci. 1990;299: 319-325.
6. Cole CW, Shea B, Bormanis J. Ancrod as prophylaxis or treatment for thromboembolism in patients with multiple trauma. Can J Surg. 1995;38:249-254.
7. Davies JA, Merrick MV, Sharp AA, Holt JM. Controlled trial of ancrod and heparin in the treatment of deep vein thrombosis of the lower limb. Lancet. 1972; 1:113-115.
8. Dormandy J, Reid H. Controlled defibrination in the treatment of peripheral vascular disease. Angiology. 1978;29:80-88.
9. Gent A, Ingram GI, Arocha-Pinango C, Fenton P, Buckley RJ. Central retinal vein thrombosis: serial treatment with defibrination, aspirin and plasminotropic drugs. Thromb Res. 1979;14:61-66.
10. Sharp A, Warren B, Paxton A, Allington MJ. Anticoagulant therapy with a purified fraction of Malayan pit viper venom. Lancet. 1968;1:493-499.
11. Tonnesen K, Sager P, Gormsen J. Treatment of severe foot ischemia by defibrination with ancrod: a randomized blind study. Scand J Clin Lab Invest. 1978; 38:431-437.
12. Barrie WW, Wood EH, Crumlish P, Forbes CD, Prentice CRM. Low-dosage ancrod for prevention of thrombotic complications after surgery for fractured neck of femur. BMJ. 1974;4:130-133.
13. Cole CW, Fournier LM, Bormanis J. Heparin-associated thrombocytopenia and thrombosis: optimal therapy with ancrod. Can J Surg. 1990;33:207-210.
14. Demers C, Ginsberg JS, Brill-Edwards P, et al. Rapid anticoagulation using ancrod for heparin-induced thrombocytopenia. Blood. 1991;78:2194-2197.
15. Lowe G, Marrice J, Fulton A, et al. Subcutaneous ancrod after operation for fractured hip: a dose-ranging and feasibility study. Thromb Haemost. 1978; 40:134-143.
16. Teasdale SJ, Zulys VJ, Mycyk T, Baird RJ, Glynn MFX. Ancrod anticoagulation for cardiopulmonary bypass in heparin-induced thrombocytopenia and thrombosis. Ann Thorac Surg. 1989;48:712-713.
17. Hossmann V, Heiss W-D, Bewermeyer H, Wiedemann G. Controlled trial of ancrod in ischemic stroke. Arch Neurol. 1983;40:803-808.
18. Olinger CP, Brott TG, Barsan WG, et al. Use of ancrod in acute or progressing ischemic cerebral infarction. Ann Emerg Med. 1988;17:1208-1209.
19. The Ancrod Stroke Study Investigators. Ancrod for the treatment of acute ischemic brain infarction. Stroke. 1994;25:1755-1759.
20. Scandinavian Stroke Study Group. Multicenter trial of hemodilution in ischemic stroke: background and study protocol. Stroke. 1985;16:885-890.
21. Lindenstrom E, Boysen G, Christiansen LW, Hansen BBR, Nielsen PW. Reliability of Scandinavian Neurological Stroke Scale. Cerebrovasc Dis. 1991;1:103-107.
22. Hacke W, Kaste M, Fieschi C, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet. 1998;352:1245-1251.
23. Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. JAMA. 1995; 274:1017-1025.
24. Mahoney FI, Barthel DW. Functional evaluation: the Barthel Index. Md State Med J. 1965;14:61-65.
25. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581-1587.
26. O'Brien PC, Fleming JA. A multiple testing procedure for clinical trials. Biometrics. 1979;35:549-556.
27. Fisher LD, van Belle G. Biostatistics: A Methodology for the Health Sciences. New York, NY: John Wiley & Sons Inc; 1993.
28. Bath P. Alteplase not yet proven for acute ischaemic stroke. Lancet. 1998;352:1238-1239.
29. Sacco RL. Risk factors, outcomes, and stroke sub-types for ischemic stroke. Neurology. 1997;49(suppl 4):S39-S44.
30. Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, Hamilton S, for the ATLANTIS Study Investigators. Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset. JAMA. 1999;282:2019-2026.
31. Marier JR, Tilley BC, Lu M, et al. Earlier treatment associated with better outcome in the NINDS TPS stroke study [abstract]. Stroke. 1999;30:244.
32. Furlan A, Higashida R, Wechsler L, et al. Intra-arterial prourokinase for acute ischemic stroke: the PROACT II study: a randomized controlled trial. JAMA. 1999;282:2003-2011.
33. BASF Pharma discontinues clinical study with ancrod based on recommendations of independent monitoring board [press release]. Available at: http: www.knoll.de. Accessed April 6, 2000.
34. Gubitz G, Counsell C, Sandercock P, Signorini D. Anticoagulants for acute ischaemic stroke. Cochrane Stroke Group Web site. Available at: http:// www.dcn.ed.ac.uk/csrg/. Accessed December 21, 1999.
35. The Multicenter Acute Stroke Trial-Europe Study Group. Thrombolytic therapy with streptokinase in acute ischemic stroke. N Engl J Med. 1996;335:145-150.
36. Multicentre Acute Stroke Trial-Italy (MAST-I) Group. Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Lancet. 1995;346:1509-1514.
37. Cole CW. Controlling acute elevation of plasma fibrinogen with ancrod. Cerebrovasc Dis. 1998;8 (supp 1):29-34.